drugset / Trial / NCT05281276
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.
Timeline
- Start
- 2022-09-20
- Primary completion
- 2024-03-26
- Completion
- 2024-03-26
Outcome
Outcome not reported
Stopped: “The overall profile does not support development for metastatic colorectal cancer”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 200 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |
| Subject | Tucidinostat | Small molecule | 30 mg | — |